Skip to main content
Log in

Lipid-lowering therapy and cholesterol levels following acute myocardial infarction: A German study of 5361 patients

  • Published:
European Journal of Epidemiology Aims and scope Submit manuscript

Abstract

Background: Current studies on secondary prevention of cardiovascular events (CARE, LIPID, 4S) illustrate the necessity of an effective lipid-lowering therapy. An important part of secondary prevention is the prompt measurement of lipids following an infarct, to be able to start therapy as quickly as possible. Aims: This study should show the general situation in the prescription of lipid-lowering drugs in patients with acute myocardial infarction (MI) and if there are gender differences in therapy and in the lipid parameters. The second aim was to determine the therapeutical conclusions for secondary prevention made in-hospital in patients with heart attacks. Methods: Post-infarct lipid parameters (total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides (TG) were examined in 5361 patients within 24 hours following an acute MI. Lipid parameters from 576 patients were measured again after 1 week. Results: 80.1% of men under examination and 81.9% of the women had suffered from their first MI. Only 9% of all patients were already under lipid-lowering therapy before the MI. After the MI TC and LDL-C levels decreased significantly in a time-dependent manner. Around 50% of patients received lipid-lowering drug, or the recommendation of one, during their hospital stay. Conclusion: The range of TC values of the patients examined was comparable to those in the CARE and the 4S secondary prevention studies. It can therefore be assumed that the results of these studies are also applicable to Germany. Nevertheless, according to existing data, therapy with lipid-lowering drugs is currently unsatisfactory, even in secondary prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383–1389.

    Google Scholar 

  2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009.

    Google Scholar 

  3. The LIPID study: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. N Engl J Med 1998; 339: 1349–1357.

  4. Enbergs A, Liese A, Heimbach M, et al. Evaluation of secondary prevention of coronary heart disease. Results of the EUROSPIRE study in the Munster region. Z Kardiol 1997; 86: 284–291.

    Google Scholar 

  5. Drexel H, Gaul GB, Grimm G, et al. Secondary prevention following coronary intervention. Survey of 13 intervention centers in Austria. Wien Klin Wochenschr 1999; 111: 643–649.

    Google Scholar 

  6. Cozma LS, Ogunko A, Rees A. Secondary prevention of hypercholesterolaemia: Results of an audit conducted in South Wales. Heart 2000; 84: E3.

    Google Scholar 

  7. Feely J, McGettigan P, Kelly A. Growth in use of statins after trials is not targeted to most appropriate patients. Clin Pharmacol Ther 2000; 67: 438–441.

    Google Scholar 

  8. Fyfe T, Baxter RH, Cochran KM, Booth EM. Plasma lipid changes after myocardial infarction. Lancet 1971; 2: 997–1001.

    Google Scholar 

  9. Mundy GR, McPherson DG. Variations in serum cholesterol levels after myocardial infarction. Med J Austr 1973; 1: 278–282.

    Google Scholar 

  10. Gore JM, Goldberg RJ, Matsumoto AS, et al. Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. Am J Cardiol 1984; 54: 722–725.

    Google Scholar 

  11. Rosenson RS. Myocardial injury: The acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993; 22: 933–940.

    Google Scholar 

  12. Ryan TJ, Anderson JL, Antmann EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary. Circulation 1996; 94: 2341–2350.

    Google Scholar 

  13. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307.

    Google Scholar 

  14. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air force/texas coronary atherosclerosis prevention study. JAMA 1998; 279: 1615–1622.

    Google Scholar 

  15. Grundy SM, Balady GJ, Criqui MH, et al. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation 1997; 95: 1683–1685.

    Google Scholar 

  16. Reckless JP. Cost-effectiveness of statins. Curr Opin Lipidol 2000; 11: 351–356.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bergmann, A., Schulze, J., Hübner, D. et al. Lipid-lowering therapy and cholesterol levels following acute myocardial infarction: A German study of 5361 patients. Eur J Epidemiol 18, 407–411 (2003). https://doi.org/10.1023/A:1024232304665

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1024232304665

Navigation